Table 2.

Predictors of puncture site hemorrhage after neuroendovascular treatment

Parameter		Total	No hemorrhage No. (%)	Hemorrhage No. (%)	P-value
Postoperative anticoagulant therapy
	Yes	145	135 (93.1)	10 (6.9)	0.583
	Heparin	53	46 (86.8)	7 (13.2)	0.019
	Argatroban	133	124 (94.0)	8 (6.0)	0.268
	No	110	105 (95.5)	5 (4.5)
Postoperative activated clotting time
	300 ≤	76	67 (88.2)	9 (11.8)	0.018
	300 >	168	162 (96.4)	6 (3.6)
No of antiplatelet agent
	3	23	19 (82.6)	4 (17.4)	0.036
	2	129	121 (93.8)	8 (6.2)	1.000
	1	36	35 (97.2)	1 (2.8)	0.702
	0	67	65 (97.0)	2 (3.0)	0.367
P2Y12 reaction units
	95 ≤	108	99 (92.4)	9 (7.6)	0.523
	95 >	38	34 (89.5)	4 (10.5)
Sheath size
	9 Fr	21	19 (90.5)	2 (9.5)	1.000
	8 Fr	27	25 (92.6)	2 (7.4)	0.546
	7 Fr	11	9 (81.8)	2 (18.2)	0.132
	7 Fr >	196	187 (95.4)	9 (5.6)	0.599
Method of hemostasis
	Manual compression	23	21 (92.3)	2 (8.7)	0.633
	Hemostasis device
	7 Fr Exoseal	10	10 (100.0)	0 (0.0)	1.000
	6 Fr Exoseal	68	66 (97.1)	2 (2.9)	0.367
	8 Fr Angioseal	99	90 (90.9)	9 (9.1)	0.101
	6 Fr Angioseal	55	53 (96.4)	2 (3.6)	0.536
Off-label use of a hemostasis device
	8 Fr Angioseal
	On-label	71	74 (91.3)	7 (8.7)	0.634
	Off-label	19	17 (90.5)	2 (9.5)
	7 Fr Exoseal
	On-label	9	9 (100.0)	0 (0.0)
	Off-label	1	1 (100.0)	0 (0.0)
Procedure time (min)
	301 <	29	27 (93.1)	2 (6.9)	0.685
	181–300	81	73 (90.1)	8 (9.9)	0.135
	180 ≥	143	138 (96.5)	5 (3.5)	0.104